FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158889234> ?p ?o ?g. }

• W2158889234 endingPage "2891" @default.
• W2158889234 startingPage "2887" @default.
• W2158889234 abstract "ABSTRACT In order to assess the prevalence of and risk factors for aminoglycoside-associated nephrotoxicity in intensive care units (ICUs), we evaluated 360 consecutive patients starting aminoglycoside therapy in an ICU. The patients had a baseline calculated glomerular filtration rate (cGFR) of ≥30 ml/min/1.73 m 2 . Among these patients, 209 (58%) developed aminoglycoside-associated nephrotoxicity (the acute kidney injury [AKI] group, which consisted of individuals with a decrease in cGFR of >20% from the baseline cGFR), while 151 did not (non-AKI group). Both groups had similar baseline cGFRs. The AKI group developed a lower cGFR nadir (45 ± 27 versus 79 ± 39 ml/min/1.73 m 2 for the non-AKI group; P < 0.001); was older (56 ± 18 years versus 52 ± 19 years for the non-AKI group; P = 0.033); had a higher prevalence of diabetes (19.6% versus 9.3% for the non-AKI group; P = 0.007); was more frequently treated with other nephrotoxic drugs (51% versus 38% for the non-AKI group; P = 0.024); used iodinated contrast more frequently (18% versus 8% for the non-AKI group; P = 0.0054); and showed a higher prevalence of hypotension (63% versus 44% for the non-AKI group; P = 0.0003), shock (56% versus 31% for the non-AKI group; P < 0.0001), and jaundice (19% versus 8% for the non-AKI group; P = 0.0036). The mortality rate was 44.5% for the AKI group and 29.1% for the non-AKI group ( P = 0.0031). A logistic regression model identified as significant ( P < 0.05) the following independent factors that affected aminoglycoside-associated nephrotoxicity: a baseline cGFR of <60 ml/min/1.73 m 2 (odds ratio [OR], 0.42), diabetes (OR, 2.13), treatment with other nephrotoxins (OR, 1.61) or iodinated contrast (OR, 2.13), and hypotension (OR, 1.83). In conclusion, AKI was frequent among ICU patients receiving an aminoglycoside, and it was associated with a high rate of mortality. The presence of diabetes or hypotension and the use of other nephrotoxic drugs and iodinated contrast were independent risk factors for the development of aminoglycoside-associated nephrotoxicity." @default.
• W2158889234 created "2016-06-24" @default.
• W2158889234 creator A5019867721 @default.
• W2158889234 creator A5039108057 @default.
• W2158889234 creator A5047062464 @default.
• W2158889234 creator A5068747774 @default.
• W2158889234 creator A5070242858 @default.
• W2158889234 creator A5082193520 @default.
• W2158889234 date "2009-07-01" @default.
• W2158889234 modified "2023-10-18" @default.
• W2158889234 title "Prevalence and Risk Factors for Aminoglycoside Nephrotoxicity in Intensive Care Units" @default.
• W2158889234 cites W1966142165 @default.
• W2158889234 cites W1967300023 @default.
• W2158889234 cites W1971123920 @default.
• W2158889234 cites W1996461070 @default.
• W2158889234 cites W1996664903 @default.
• W2158889234 cites W1997423693 @default.
• W2158889234 cites W2008294830 @default.
• W2158889234 cites W2024998738 @default.
• W2158889234 cites W2028461446 @default.
• W2158889234 cites W2029723446 @default.
• W2158889234 cites W2031682536 @default.
• W2158889234 cites W2042241561 @default.
• W2158889234 cites W2047474179 @default.
• W2158889234 cites W2055864845 @default.
• W2158889234 cites W2058386504 @default.
• W2158889234 cites W2076415782 @default.
• W2158889234 cites W2083643674 @default.
• W2158889234 cites W2085440534 @default.
• W2158889234 cites W2115307833 @default.
• W2158889234 cites W2122316430 @default.
• W2158889234 cites W2131419242 @default.
• W2158889234 cites W2139937737 @default.
• W2158889234 cites W2145355130 @default.
• W2158889234 cites W2148589029 @default.
• W2158889234 cites W2159320641 @default.
• W2158889234 cites W2159869759 @default.
• W2158889234 cites W2165914204 @default.
• W2158889234 cites W2167293877 @default.
• W2158889234 cites W2172287968 @default.
• W2158889234 cites W2328554661 @default.
• W2158889234 cites W2342408386 @default.
• W2158889234 doi "https://doi.org/10.1128/aac.01430-08" @default.
• W2158889234 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2704674" @default.
• W2158889234 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19364846" @default.
• W2158889234 hasPublicationYear "2009" @default.
• W2158889234 type Work @default.
• W2158889234 sameAs 2158889234 @default.
• W2158889234 citedByCount "135" @default.
• W2158889234 countsByYear W21588892342012 @default.
• W2158889234 countsByYear W21588892342013 @default.
• W2158889234 countsByYear W21588892342014 @default.
• W2158889234 countsByYear W21588892342015 @default.
• W2158889234 countsByYear W21588892342016 @default.
• W2158889234 countsByYear W21588892342017 @default.
• W2158889234 countsByYear W21588892342018 @default.
• W2158889234 countsByYear W21588892342019 @default.
• W2158889234 countsByYear W21588892342020 @default.
• W2158889234 countsByYear W21588892342021 @default.
• W2158889234 countsByYear W21588892342022 @default.
• W2158889234 countsByYear W21588892342023 @default.
• W2158889234 crossrefType "journal-article" @default.
• W2158889234 hasAuthorship W2158889234A5019867721 @default.
• W2158889234 hasAuthorship W2158889234A5039108057 @default.
• W2158889234 hasAuthorship W2158889234A5047062464 @default.
• W2158889234 hasAuthorship W2158889234A5068747774 @default.
• W2158889234 hasAuthorship W2158889234A5070242858 @default.
• W2158889234 hasAuthorship W2158889234A5082193520 @default.
• W2158889234 hasBestOaLocation W21588892341 @default.
• W2158889234 hasConcept C126189478 @default.
• W2158889234 hasConcept C126322002 @default.
• W2158889234 hasConcept C134018914 @default.
• W2158889234 hasConcept C159641895 @default.
• W2158889234 hasConcept C177713679 @default.
• W2158889234 hasConcept C2777787772 @default.
• W2158889234 hasConcept C2780306776 @default.
• W2158889234 hasConcept C2780472472 @default.
• W2158889234 hasConcept C29730261 @default.
• W2158889234 hasConcept C2987404301 @default.
• W2158889234 hasConcept C501593827 @default.
• W2158889234 hasConcept C555293320 @default.
• W2158889234 hasConcept C71924100 @default.
• W2158889234 hasConcept C86803240 @default.
• W2158889234 hasConcept C89423630 @default.
• W2158889234 hasConcept C90924648 @default.
• W2158889234 hasConceptScore W2158889234C126189478 @default.
• W2158889234 hasConceptScore W2158889234C126322002 @default.
• W2158889234 hasConceptScore W2158889234C134018914 @default.
• W2158889234 hasConceptScore W2158889234C159641895 @default.
• W2158889234 hasConceptScore W2158889234C177713679 @default.
• W2158889234 hasConceptScore W2158889234C2777787772 @default.
• W2158889234 hasConceptScore W2158889234C2780306776 @default.
• W2158889234 hasConceptScore W2158889234C2780472472 @default.
• W2158889234 hasConceptScore W2158889234C29730261 @default.
• W2158889234 hasConceptScore W2158889234C2987404301 @default.
• W2158889234 hasConceptScore W2158889234C501593827 @default.
• W2158889234 hasConceptScore W2158889234C555293320 @default.
• W2158889234 hasConceptScore W2158889234C71924100 @default.

• next